The approval was based on two phase 1 crossover studies, which compared zanubrutinib tablets with the capsule formulation in healthy adult participants.

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...